Scientific Presentations

2022

The Society for Immunotherapy of Cancer 37th Annual Meeting and Pre-Conference Programs
SITC Presentation 2022 | November 2022

A Multicenter Phase 2 Study of Sotigalimab (CD40 Agonist) in Combination With Neoadjuvant Chemoradiation for Resectable Esophageal and Gastroesophageal Junction (GEJ) Cancers
ESMO Poster 2022 | September 2022

Distinct Biosignatures Associate with Survival After Chemoimmunotherapy in a Randomized, Three-arm Phase II Study in Patients with Metastatic Pancreatic Cancer
ASCO Presentation 2022 | June 2022

Intratumoral CD40 Agonist Sotigalimab (APX005M) with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in Metastatic Melanoma
AACR Presentation 2022 | April 2022

Elucidating Factors of Therapeutic Response to Immunotherapy Combined with Neoadjuvant Radiation Therapy for Rectal Cancer
Keystone Poster 2022 | March 2022

2021

Multi-Omic Multi-Parameter Circulating Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Activation Signatures in the Pancreatic Cancer Setting
SITC Poster 2021 | November 2021

Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
SITC Poster 2021 | November 2021

Innate: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer to Elucidate Local and Systemic Therapeutic Response
SITC Poster 2021 | November 2021

Gemcitabine and nab-Paclitaxel ± Nivolumab ± CD40 Agonistic Monoclonal Antibody Sotigalimab (APX005M) in Participants with Untreated Metastatic Pancreatic Adenocarcinoma: Phase 2 Final Results
ASCO Poster 2021 | June 2021

2019

Intratumoral CD40 Agonist (APX005M) in Combination with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in CPI Treatment Naïve Metastatic Melanoma
CICON Poster | September 2019

Phase 1b/2 Study of CD40 Agonistic Antibody APX005M in Combination with Nivolumab (Nivo) in Subjects with Metastatic Melanoma (M) and Subjects with Non-Small Cell Lung Cancer (NSCLC)
AACR Poster | April 2019

A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients
AACR Presentation | March 2019

A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Ductal Pancreatic Adenocarcinoma (PDAC) Patients
ASCO GI Abstract | January 2019

2017

First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
SITC Presentation | November 2017

Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
SITC Poster | November 2017

A Pilot Study to Evaluate The Clinical and Immunological Effects of Incorporating a CD40-Agonistic Antibody into the Multimodality Treatment of Resectable Esophageal and GE Junction Cancersrcoma
SITC Poster | November 2017

A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma
SITC Poster | November 2017

A Phase Ib/II Study of CD40 Agonistic Monoclonal Antibody (APX005M) Together with Gemcitabine and nab-Paclitaxel with or without Nivolumabin Untreated Metastatic Pancreatic Adenocarcinoma Patients
SITC Poster | November 2017